HC Wainwright Reaffirms “Buy” Rating for Maze Therapeutics (NASDAQ:MAZE)

Maze Therapeutics (NASDAQ:MAZE)‘s stock had its “buy” rating reissued by HC Wainwright in a research note issued on Thursday, Benzinga reports. They currently have a $110.00 price objective on the stock. HC Wainwright’s price objective indicates a potential upside of 291.60% from the company’s previous close.

A number of other brokerages also recently issued reports on MAZE. TD Cowen upgraded Maze Therapeutics to a “strong-buy” rating in a research report on Monday, August 24th. Weiss Ratings reissued a “sell (d-)” rating on shares of Maze Therapeutics in a research note on Monday. Citigroup assumed coverage on shares of Maze Therapeutics in a research report on Wednesday. They issued a “buy” rating and a $50.00 price objective on the stock. Wall Street Zen cut Maze Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Finally, Wedbush restated an “outperform” rating and set a $48.00 price target on shares of Maze Therapeutics in a research report on Wednesday. Three research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $63.40.

Maze Therapeutics Stock Down 1.0%

MAZE stock opened at $28.09 on Thursday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.31 and a current ratio of 18.31. The company has a market capitalization of $1.56 billion, a price-to-earnings ratio of -11.15 and a beta of 2.17. Maze Therapeutics has a fifty-two week low of $21.95 and a fifty-two week high of $53.65. The stock has a fifty day moving average of $27.18 and a 200-day moving average of $29.17.

Maze Therapeutics (NASDAQ:MAZE) last posted its earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.76). As a group, equities research analysts predict that Maze Therapeutics will post -2.72 earnings per share for the current year.

Insider Activity

In other news, CEO Jason V. Coloma sold 11,411 shares of the company’s stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $26.01, for a total transaction of $296,800.11. Following the sale, the chief executive officer directly owned 27,362 shares of the company’s stock, valued at $711,685.62. This represents a 29.43% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CMO Harold Bernstein sold 9,705 shares of Maze Therapeutics stock in a transaction on Friday, September 4th. The stock was sold at an average price of $26.22, for a total transaction of $254,465.10. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 191,459 shares of company stock worth $5,263,539 in the last quarter. 5.30% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in MAZE. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in Maze Therapeutics in the second quarter worth $48,000. Royal Bank of Canada raised its holdings in shares of Maze Therapeutics by 214.1% in the first quarter. Royal Bank of Canada now owns 2,029 shares of the company’s stock worth $61,000 after buying an additional 1,383 shares during the period. Quantbot Technologies LP purchased a new position in Maze Therapeutics during the 2nd quarter valued at $80,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Maze Therapeutics during the fourth quarter worth $145,000. Finally, IFP Advisors Inc purchased a new position in Maze Therapeutics in the 4th quarter worth about $146,000.

About Maze Therapeutics

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetically driven diseases. The company combines human genetics, functional genomics and drug discovery technologies through its Maze Compass platform to identify disease mechanisms and develop therapies designed to address the underlying causes of disease.

Maze’s lead program, MZE001, is an oral small-molecule inhibitor of glycogen synthase being developed for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles and other tissues.